BARCELONA, Spain, November 5, 2012 /PRNewswire/ --
Life Science Entrepreneurs S.L.U., a company dedicated to the early-stage development of high-risk/very high return ventures, announced today the conclusion of a first investment for an antiplatelet drug candidate code-named NmC.
Private investors from Barcelona, Geneva and Basel, all active in medical applications of life sciences, have funded the assays to confirm the safety and efficacy of the cardiovascular drug NmC.
"NmC might prevent cardiovascular incidents thanks to the unique way it dilutes the blood of at-risk patients", said François Arcand, President of Life Science Entrepreneurs S.L.U. "The drug candidate catches the interest of experts in the field because its novel mechanism of action could set it apart from antiplatelets like the standard-of-care Plavix® or the newcomer Eliquis®".
The molecule has been licensed from a foreign university. In early 2013, Life Science Entrepreneurs S.L.U. will raise two million euro to conduct a complete set of regulatory pre-clinical assays from Spanish and foreign investors.
Life Science Entrepreneurs S.L. develops scientific discoveries up to the completion of a viable proof-of-concept, when successful technologies are susceptible to be acquired by well-funded specialized organizations. For more, see http://www.LifSciE.com
Français : http://www.lifscie.com/fr/enemce/
SOURCE Life Science Entrepreneurs S.L.U.